Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;13(5):848-860.
doi: 10.1111/cts.12769. Epub 2020 Mar 31.

Genetic Diversity in Drug Transporters: Impact in African Populations

Iris Rajman  1 , Laura Knapp  2 , Imad Hanna  3
Affiliations
Review

Genetic Diversity in Drug Transporters: Impact in African Populations

Iris Rajman et al. Clin Transl Sci. 2020 Sep.

Erratum in

Abstract

Polymorphisms in drug transporters, like the adenosine triposphate-binding cassette (ABC) and solute carrier (SLC) superfamilies, may contribute to the observed diversity in drug response in African patients. This review aims to provide a comprehensive summary and analysis of the frequencies and distributions in African populations of ABC and SLC variants that affect drug pharmacokinetics (PK) and pharmacodynamics (PD). Of polymorphisms evaluated in African populations, SLCO1B1 rs4149056 and SLC22A6 rs1158626 were found at markedly higher frequencies than in non-African populations. SLCO1B1 rs4149056 was associated with reduction in rifampin exposure, which has implications for dosing this important anti-tuberculosis therapy. SLC22A6 rs1158626 was associated with increased affinity for antiretroviral drugs. Genetic diversity in SLC and ABC transporters in African populations has implications for conventional therapies, notably in tuberculosis and HIV. More PK and PD data in African populations are needed to assess potential for a different response to drugs compared with other global populations.

PubMed Disclaimer

Conflict of interest statement

I.R. is an employee of Novartis NKK, Tokyo, Japan. L.K. is an employee of PharmaGenesis London, London, UK. I.H. is an employee of Novartis, East Hanover, NJ, USA. All authors declared no additional competing interests for this work.

Figures

Figure 1
Figure 1
Flow of studies through the search and selection process. PD, pharmacodynamics; PK, pharmacokinetics.
See this image and copyright information in PMC

References

    1. Mekonnen, A.B. , Alhawassi, T.M. , McLachlan, A.J. & Brien, J.E. Adverse drug events and medication errors in African hospitals: a systematic review. Drugs Real World Outcomes 5, 1–24 (2018). - PMC - PubMed
    1. Rajman, I. , Knapp, L. , Morgan, T. & Masimirembwa, C. African genetic diversity: implications for cytochrome P450‐mediated drug metabolism and drug development. EBioMedicine 17, 67–74 (2017). - PMC - PubMed
    1. Camp, D. , Garavelas, A. & Campitelli, M. Analysis of physicochemical properties for drugs of natural origin. J. Nat. Prod. 78, 1370–1382 (2015). - PubMed
    1. Ahmed, S. , Zhou, Z. , Zhou, J. & Chen, S.Q. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics Proteomics Bioinform. 14, 298–313 (2016). - PMC - PubMed
    1. World Health Organization . Global tuberculosis report. <www.who.int/tb/publications/global_report/en/> (2018). Accessed July 31, 2019.

Publication types

MeSH terms

Substances